The present disclosure provided methods and systems for diagnosing diseases and monitoring their progression and therapeutic responses by detecting a presence or absence, or an increase or decrease, of one or more substances in a sample.

Technology described herein includes a method that includes obtaining an image of a fluid of a microfluidic analysis system. The microfluidic analysis system includes or receives a container that contains the fluid for measurement of analyte or quality determination. A region of interest (ROI) is identified based on the image. The ROI is a set of pixel values for use in the measurement of the analyte or the quality determination of the fluid, fluidic path, or measuring system. Identifying the ROI includes: determining an alignment of the container of the fluid with the imaging device based on the image, and identifying the ROI based on information about the measurement of the fluid or based on information about non-analyte features of the fluid. An analysis of the image of the fluid is performed using the set of pixel values of the ROI.

Disclosed are colloidal gold test paper for double-window detection of fecal occult blood and an application thereof, and the colloidal gold test paper comprises a left reagent strip and a right reagent strip; the reagent strip is provided with a sample pad, a label pad, a nitrocellulose membrane and a water absorption pad; and the right reagent strip contains a mouse anti-human hemoglobin monoclonal antibody treated with a treatment solution. According to the invention, by double-window detection, the occurrence of HOOK phenomenon can be delayed, and the accuracy of colloidal gold detection can be improved.

The kit for quantitative analysis of C-Reactive Protein (CRP) according to an embodiment of the present application may comprises: a first composition including a hemolytic reagent for hemolyzing at least a portion of blood cells in a blood sample; and a second composition including an anti-CRP antibody for antigen-antibody reaction of CRP contained in the hemolyzed sample.

A tangent flow hemolysis blood testing assembly, device and method are described herein. The presently disclosed and claimed inventive concept(s) relate to a device(s), kit(s), and method(s) for injecting a patient's liquid test sample into a reaction vessel. More specifically, the presently disclosed and claimed inventive concept(s) relate to an improved liquid test sample injection device that comprises a plug that forms an airtight seal that facilitates the active injection of a liquid test sample into a reaction vessel, and kits and methods of use related thereto.

The present disclosure relates to systems and methods for measuring glycated A1c hemoglobin. A glycated hemoglobin level measuring system includes a sample testing apparatus having a microchannel that compresses a blood sample traveling through, a first pair of electrodes coupled to the microchannel, and a second pair of electrodes coupled to the microchannel. The glycated hemoglobin level measuring system further includes an analysis apparatus having sensors coupled to the first and second pairs of electrodes and configured to calculate a travel time taken by a red blood cell to pass through the first and second pairs of electrodes. The glycated hemoglobin level measuring system can use the travel time to measure a rigidity of the red blood cells and the corresponding glycated hemoglobin level.

The present disclosure pertain to methods of detecting hypoxemia in a subject by: (1) receiving a blood sample from the subject; (2) measuring the T.sub.2 relaxation time constant of the blood cell (e.g., blood cell pellet) of the blood sample (T.sub.2P value); and (3) correlating the measured T.sub.2P value to hypoxemia. The methods of the present disclosure also include a step of correlating the measured T.sub.2P value to the subject's susceptibility to one or more hypoxemia-related conditions. The present disclosure also pertains to systems for detecting hypoxemia in a subject in accordance with the methods of the present disclosure.

A tangent flow hemolysis blood testing assembly, device and method are described herein.

Provided herein are systems and methods of assessing a concentration of iron in a body fluid sample, such as whole blood. Systems include a highly stable, fast reacting, and accurate sensing area of a sensor for contacting with a body fluid sample, wherein upon contact, the body fluid sample causes a color change to the sensor that correlates with the concentration of iron in the body fluid sample. The disclosed systems and methods generate one or more signal outputs of light intensity data, from which the concentration of iron in the body fluid sample is determined.

Technology described herein includes a method that includes obtaining an image of a fluid of a microfluidic analysis system. The microfluidic analysis system includes or receives a container that contains the fluid for measurement of analyte or quality determination. A region of interest (ROI) is identified based on the image. The ROI is a set of pixel values for use in the measurement of the analyte or the quality determination of the fluid, fluidic path, or measuring system. Identifying the ROI includes: determining an alignment of the container of the fluid with the imaging device based on the image, and identifying the ROI based on information about the measurement of the fluid or based on information about non-analyte features of the fluid. An analysis of the image of the fluid is performed using the set of pixel values of the ROI.